Brind.

Emergent BioSolutions received a contract modification from BARDA to supply a vaccine, which had previously been approved by the FDA.

1 report, 1 independent Updated Sep 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Emergent BioSolutions Department of Health & Human Services Food and Drug Administration

Keep exploring

The entities involved

Emergent BioSolutions
multinational biopharmaceutical company headquartered in Gaithersburg, Maryland, USA
- Emergent BioSolutions and Precigen are two healthcare companies that are currently competing for investment.Sat 00:43
Department of Health & Human Services
government department in the state of Victoria, Australia
- The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02
- The FDA reviewed risks and loosened the label on testosterone replacement therapy (TRT) following an attempt by the Trump administration to reverse its decline.Mon 12:10
Food and Drug Administration
government organization in Nonthaburi, Thailand
- Trump is expected to nominate Heidi Overton to lead the Food and Drug Administration.Mon 15:49
- In 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Mon 12:46

Coverage

Newest first; wire copies grouped

Sep 2GlobeNewswireEmergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use GAITHERSBURG, Md., S